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Abstract 
Background: Diabetes induces long bone loss and aggravation of periodontitis‑induced alveolar bone loss. Simv‑
astatin (SIM), which is a lipid‑lowering agent is known to have an anabolic effect on bone. Therefore, we investigated 
effect of SIM on tibial and alveolar bone loss in type 1 diabetic rats with periodontitis.
Methods: Rats were divided into control (C), diabetes with periodontitis (DP), and diabetes with periodontitis treated 
with SIM (DPS) groups. DP and DPS groups were intravenously injected with streptozotocin (50 mg/kg), and C group was 
injected with citrate buffer. Seven days later (day 0), periodontitis was induced by ligatures of mandibular first molars. 
DP and DPS groups were orally administered vehicle or SIM (30 mg/kg) from day 0 to days 3, 10, or 20. Alveolar and 
tibial bone loss was measured using histological and m‑CT analysis alone or in combination. Osteoclast number and 
sclerostin‑positive osteocytes in tibiae were evaluated by tartrate‑resistant acid phosphatase and immunohistochemical 
staining, respectively. Glucose, triglyceride (TG), cholesterol (CHO), and low‑density lipoprotein (LDL) were evaluated.
Results: Consistent with diabetes induction, the DP group showed higher glucose and TG levels at all timepoints 
and higher CHO levels on day 20 than C group. Compared to the DP group, the DPS group exhibited reduced levels 
of glucose (day 3), TG (days 10 and 20), CHO, and LDL levels (day 20). Bone loss analysis revealed that the DP group 
had lower bone volume fraction, bone mineral density, bone surface density, and trabecular number in tibiae than C 
group at all timepoints. Interestingly, the DPS group exhibited elevation of these indices at early stages compared to 
the DP group. The DPS group showed reduction of osteoclasts (day 3) and sclerostin‑positive osteocytes (days 3 and 
20) compared with the DP group. There was no difference in alveolar bone loss between DP and DPS groups.
Conclusions: These results suggest that SIM attenuates tibial, but not alveolar bone loss in type 1 diabetic rats with 
periodontitis. Moreover, attenuation of tibial bone loss by SIM may be related to inhibition of osteoclast formation and 
reduction of sclerostin expression.
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Background
Simvastatin (SIM) inhibits 3-hydroxy-3-methylglutaryl 
coenzyme A reductase and subsequently decreases cho-
lesterol synthesis [1]. Thus, SIM is prescribed as an anti-
hyperlipidemic agent for reducing cardiovascular disease. 
In addition, SIM has anti-inflammatory, angiogenic, and 
bone anabolic actions, which have generated interest 
in clinical fields related to inflammatory, ischemic, and 
bone diseases [2–4].
Periodontitis is an inflammatory disease that induces 
alveolar bone loss. In periodontitis animal models, SIM 
treatment has a beneficial effect on alveolar bone level 
[5–8]. Additionally, SIM treatment resulted in improved 
radiographic defect depth in periodontitis patients [1, 9, 
10]. The prevalence or severity of periodontitis is affected 
by systemic conditions including menopause, medica-
tion, smoking, and metabolic syndrome. SIM treatment 
prevents alveolar bone loss in ovariectomized rats with 
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alveolar bone loss in periodontitis rats [12]. In smokers 
with chronic periodontitis, SIM treatment in combina-
tion with nonsurgical treatment improves bone fills [13]. 
In addition, SIM treatment inhibits lipopolysaccharide 
(LPS)-induced alveolar bone loss in Zucker fatty rats with 
increased body weight and high cholesterol level [14].
A complication of diabetes mellitus is bone fractures 
[15]. As an anabolic agent, SIM is effective in the treat-
ment of facture healing [16]. However, the activity of SIM 
on bone anabolism under diabetic conditions remains 
controversial. Bone mineral density (BMD) in SIM-
treated subjects with type 2 diabetes mellitus did not 
show a significant difference compared with untreated 
subjects with type 2 diabetes mellitus [17]. In con-
trast, SIM application on calvaria defects was shown to 
enhance bone defect healing in rats with streptozotocin 
(STZ)-induced diabetes [18].
Periodontitis is another complication of diabetes 
mellitus. Diabetic patients with difficulty controlling 
glucose levels are more likely to suffer from periodon-
titis compared with those with sufficient diabetes con-
trol and healthy subjects [19, 20]. One group reported 
that local SIM application improved alveolar bone fill 
in patients with type 2 diabetes and chronic periodon-
titis when combined with scaling and root planing [21]. 
Until now, systemic SIM administration in diabetic 
subject with periodontitis has not been evaluated. As 
diabetic patients can show hyperlipidemia, aggravated 
alveolar bone loss due to periodontitis, and long bone 
loss, it is necessary to evaluate the effect of systemic 
administration of SIM. Studying the effect of systemic 
SIM administration on bone loss using a diabetic ani-
mal model with periodontitis may have translational 
utility in the clinical field. Animal models of STZ-
induced diabetes display pancreatic β-cell destruction 
and are commonly used as an experimental approach to 
the study of human type 1 diabetes; however, extrapola-
tion of findings from these models to humans remains 
challenging due to potential toxicity in the liver and 
kidneys [22]. Nevertheless, rats with STZ-induced type 
1 diabetes and periodontitis provide a good model for 
observing coincident tibial and alveolar bone loss. In 
our previous study, rats with STZ-induced diabetes and 
periodontitis showed increased alveolar bone loss that 
was attributed to elevation of bone resorption and inhi-
bition of bone formation after the induction of peri-
odontitis compared with control rats [23]. Based on 
these observations, we hypothesized that SIM could 
attenuate bone loss during the progression of type 1 
diabetes and periodontitis and determined the effect of 
systemic SIM treatment on alveolar and tibial bone loss 
using rats with STZ-induced type 1 diabetes and liga-
ture-induced periodontitis.
Methods
Animal model with diabetes and periodontitis 
and simvastatin treatment
F344 rats (male, 6 weeks old) were purchased from Shi-
zuoka Laboratory Center (Shizuoka, Japan). To minimize 
distress, all rats were housed three per a cage in specific 
pathogen-free conditions on a 12  h light/dark cycle at 
constant temperature (22 °C) and received standard chow 
and water ad  libitum. After acclimation for 1 week, rats 
were randomly assigned to three groups: control group 
(C), diabetes with periodontitis group (DP), or diabetes 
with periodontitis treated with SIM group (DPS). After 
fasting for 18 h, DP and DPS groups were intravenously 
injected with STZ (50  mg/kg; Sigma-Aldrich, St. Louis, 
MO, USA) dissolved in 0.1 M citrate buffer. The C group 
was injected with citrate buffer alone. Seven days after 
injection (day 0), blood glucose levels were measured 
from the tail vein using a glucometer (Accu-Check active 
system, Roche, Mannheim, Germany). Rats with fasting 
blood glucose levels over 300 mg/dl were considered dia-
betic. On day 0, all rats were intraperitoneally injected 
with a mixture of zoletil 50 (30  mg/kg; Virbac, Carros, 
France) and rompun (10  mg/kg; Bayer Korea, Ansan, 
Korea). Following injection, periodontitis was induced 
in the DP and DPS groups by ligatures of the mandibu-
lar first molars with dental floss to induce biofilm forma-
tion. SIM (30 mg/kg/day, Chong Kun Dang Pharm, Seoul, 
Korea) was given daily via oral gavage to the DPS group, 
and saline was given to the DP group. The C group was 
sacrificed on day 0 (n = 6), and DP and DPS groups were 
sacrificed on days 3 (DP, n = 6; DPS, n = 7), 10 (DP, n = 4; 
DPS, n = 4), and 20 (DP, n = 7; DPS, n = 9). The experi-
mental protocol is presented in Fig. 1a. The maintenance 
of diabetes was confirmed by measuring body weight and 
the fasting glucose level during the experimental period. 
The animal protocols were approved by the Institutional 
Animal Care and Use Committee of Yonsei University 
(Approval Number: 2015-0345).
Serum biochemistry
Serum was obtained from all rats under fasting condi-
tions at sacrifice. Levels of serum triglyceride (TG), total 
cholesterol (CHO), and low-density lipoprotein (LDL) 
were measured using a Konelab prime 30i automated 
analyzer (Thermo scientific, Waltham, MA, USA).
Histological analysis of alveolar and tibial bones
Mandibles dissected from rats were fixed with 10% neu-
tral-buffered formalin for 24 h and embedded in paraffin 
after decalcification with 10% ethylenediaminetetraacetic 
acid (EDTA) for 2 months. Sagittal sectioned mandibles 
were cut at 4  μm thickness. Sections, including clear 
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dental pulp of the mesial and distal roots of the first 
molar, were selected and stained with hematoxylin and 
eosin (H&E). For determination of alveolar bone loss, the 
distance between the cementoenamel junction (CEJ) and 
the alveolar bone crest (ABC) was measured in the dis-
tal area, and the alveolar bone area was measured in the 
region of interest (ROI) of the furcation. Then, the alveo-
lar bone area in the ROI was divided by the ROI. The ROI 
was 0.8 mm downward from the top of the furcation. For 
the evaluation of alveolar bone formation, the light pink 
unmineralized osteoid area between the alveolar bone 
surface and osteoblasts was measured in the ROI, which 
was 0.5  mm downward from the ABC in the furcation. 
For the determination of tibial bone loss, tibiae were fixed 
with 10% neutral-buffered formalin. After 24 h of fixation, 
left tibiae were decalcified with 10% EDTA for 1 month 
after which paraffin embedding was performed. The 
paraffin blocks were sectioned as previously described, 
and the sections containing the clear proximal epiphy-
seal growth plate were selected and H&E stained. The 
ROI for trabecular bone extended 1.0 mm from 1.0 mm 
below the growth plate toward the diaphysis (excluding 
the outer cortical shell). The area of remaining trabecular 
bone in the ROI was measured and then divided by the 
ROI. An Aperio AT2 Digital Whole Slide scanner (Leica 
Microsystems Inc., Buffalo Grove, IL, USA) and Aperio 
ImageScope software (version 12.3.2.2013, Aperio Tech-
nologies Inc., Vista, CA, USA) were used for the slide 
scanning and analysis, respectively.
Micro‑computed tomography analysis of tibiae
Right tibiae were scanned using micro-computed tomog-
raphy (m-CT, Skyscan1076, Kontich, Belgium). The scan-
ning parameters were set at 70  kV and 139  μA with an 
exposure time of 1475 ms and a resolution of 18 μm. The 
trabecular bone structures extending 2 mm from 0.7 mm 
below the epiphyseal growth plate were chosen as the 
ROI [24], and three-dimensional images of the specimens 
were reconstructed. Bone volume fraction (BVF), BMD, 
bone surface density (BSD), and trabecular number (Tb. 
N) in the ROI were calculated using the NRecon software 
(Bruker SkyScan, Aartselaar, Belgium).
Tartrate‑resistant acid phosphatase staining
To identify osteoclast formation in tibiae sections, tar-
trate-resistant acid phosphatase (TRAP) staining was 
performed using a TRAP stain kit (Wako chemicals, 
Osaka, Japan). Methyl green (Trevigen, Gaithersburg, 
MD, USA) was used for the counterstaining, and slides 
were scanned as described above. The number of TRAP-
positive cells in the ROI were counted along the trabec-
ular bone surface, divided by the bone length, and then 
divided by the percentage of bone area remaining in the 
ROI. The ROI was area extended 1.0  mm from 1.0  mm 
below the growth plate toward the diaphysis (excluding 
the outer cortical shell).
Immunohistochemistry staining
To assess sclerostin expression in tibiae, tibiae sections 
were deparaffinized in xylene and rehydrated through 
ethanol series. Sections were incubated with Trypsin 
Enzymatic Antigen Retrieval Solution (Abcam, Cam-
bridge, UK) for 15 min at 37  °C followed by immersion 
in 3%  H2O2 in methanol for 20 min to block endogenous 
peroxidase. After blocking in normal horse serum (Vec-
tor Laboratories, Burlingame, CA, USA) for 20  min, 
the sections were incubated overnight at 4  °C with goat 
anti-sclerostin antibody (1:50 dilution, R&D Systems, 
Fig. 1 Experimental scheme and the effects of SIM on body weight 
and fasting glucose level. Rats were divided into three groups: C, DP, 
and DPS. a Experimental scheme: 7 days after induction of diabetes 
by STZ (50 mg/kg) injection, periodontitis was induced by ligatures 
of the mandibular first molars using dental floss (day 0). After 
placement of the ligatures, the DPS group was orally administered 
SIM (30 mg/kg) daily for a duration of 3, 10, or 20 days. b Body weight 
and c fasting glucose level in each group. Data are presented as the 
mean ± SE. *P < 0.05 compared with the C group. **P < 0.05
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Minneapolis, MN, USA). After incubation with anti-goat 
secondary antibody (Vector Laboratories) for 20  min, 
sections were developed with 3,3-diaminobenzidine tet-
rahydrochloride substrate chromogen system (DAKO, 
Botany, Australia) and counterstained with methyl green. 
Slides were scanned as described above. The number of 
sclerostin-positive osteocytes in the ROI was divided by 
the number of total osteocytes in the ROI. The ROI was 
the same as the ROI for osteoclast counting.
Statistical analysis
All statistical comparisons were made using a statisti-
cal analysis program (SPSS, Chicago, IL, USA). Sig-
nificant differences were determined using one-way 
analysis of variance with Scheffé’s post hoc test. A value 
of P < 0.05 was considered statistically significant. Data 
are expressed as the mean ± standard error (SE).
Results
SIM reduces body weight and fasting glucose level 
at an early stage in diabetic rats with periodontitis
Body weight was reduced and fasting glucose level was 
elevated in the DP and DPS groups compared with the 
C group for the duration of the experimental period 
(Fig. 1b, c). Interestingly, the DPS group had higher body 
weight and lower fasting glucose level than the DP group 
on day 3.
Serum TG, CHO, and LDL levels are reduced with SIM 
treatment
TG level was higher in the DP group than the C group 
during the experimental period but was lower in the DPS 
group than the DP group on days 10 and 20 (Fig.  2a). 
On day 20, CHO level was higher in the DP group than 
the C group, but was lower in the DPS group than the 
DP group (Fig. 2b). In terms of LDL, the DPS group also 
showed lower level than the DP group on day 20 (Fig. 2c).
Alveolar bone loss is not attenuated by SIM treatment
The effect of SIM on alveolar bone loss and formation 
of first molars was estimated by measuring the CEJ- 
ABC distance in the distal area (Fig. 3a, b), the alveolar 
bone area in the furcation (Fig. 3a, c), and the osteoid 
area in the furcation (Fig.  3d). The CEJ-ABC distance 
was higher in the DP and DPS groups than the C group, 
and there was no difference between the DP and DPS 
groups. Alveolar bone area in the DP group was lower 
than the C group for the duration of the experimental 
period, and the DPS group was lower on days 10 and 
20. However, there was no difference between the DP 
and DPS groups. Similarly, the osteoid area was lower 
in the DP and DPS groups than the C group for the 
entire experimental period, and there was no difference 
between the DP and DPS groups.
SIM reduces tibial bone loss
The effect of SIM on tibial bone loss was estimated by 
m-CT (Fig.  4a) and histological analysis (Fig.  4b). In 
m-CT analysis, levels of BVF, BMD, BSD, and Tb. N 
were lower in the DP group than the C group during the 
experimental period. On day 3, the DPS group showed 
higher levels of BVF, BSD, and Tb. N than the DP 
group. Additionally, on day 10, the DPS group showed 
increased levels of BVF and BMD compared with the 
DP group. Finally, on day 20, there was no difference 
between the DPS and DP groups. In histological analy-
sis, tibial bone area in the DP group was lower than that 
of the C group at all timepoints, but the DPS group was 
only lower than the C group on day 20. Interestingly, 
tibial bone area was higher in the DPS group than the 
DP group for the duration of the experimental period.
Osteoclast formation and sclerostin expression in tibiae 
are reduced with SIM treatment
The effect of SIM on osteoclast formation in tibiae was 
estimated by TRAP staining (Fig.  5a). On day 3, the 
number of TRAP-positive osteoclasts was higher in 
the DP group than the C group and was lower in the 
DPS group than the DP group. There was no difference 
among the three groups on days 10 and 20. Sclerostin 
expression in osteocytes was estimated by immunohis-
tochemistry and subsequent quantification of positive 
cells relative to the total number of osteocytes (Fig. 5b). 
On days 3 and 10, the proportion of sclerostin-posi-
tive osteocytes was higher in the DP group than the C 
group. Further, sclerostin-positive osteocyte propor-
tions were reduced in the DPS group compared with 
the DP group on days 3 and 20.
Discussion
Patients with poorly controlled type 1 diabetes often pre-
sent with elevated TG, CHO, and LDL levels [25]. Mice 
with STZ-induced diabetes also show higher levels of 
glucose, TG, CHO, and LDL compared with normal mice 
[26]. Consistent with these reports, our study found that 
STZ-treated rats with periodontitis exhibited high levels 
of glucose, TG, and CHO as well as severe weight loss, 
indicating successful induction of diabetes in our model. 
In the previous study, the lipid-lowering agent, SIM, 
reduced CHO and LDL in patients with type 1 diabetes 
[25]. In this study, systemic SIM treatment attenuated 
weight loss and decreased glucose, TG, CHO, and LDL 
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levels in STZ-treated rats with periodontitis. The benefi-
cial effects of SIM on weight loss and high glucose level 
appeared transiently at an early stage. However, the anti-
hyperlipidemic effects of SIM were more prominent for 
the duration of administration. These results suggest 
that systemic SIM treatment had promising effects dur-
ing the experimental period in type 1 diabetic rats with 
periodontitis.
Bone loss is determined by bone resorption of osteo-
clasts and bone formation of osteoblast. Increases in 
cathepsin K and the ratio of receptor activator of nuclear 
factor kappa-Β ligand (RANKL) to osteoprotegerin in 
tibiae were noted in mice with STZ-induced diabetes 
[24]. Another group also reported that mice with STZ-
induced diabetes had elevated expression of osteoclast-
specific genes (matrix metallopeptidase-9, carbonic 
anhydrase II, RANKL) in tibiae than non-diabetic mice 
[27]. These studies suggest that bone resorption in tibiae 
increases under type 1 diabetic conditions. In accordance 
with these reports, we found that the DP group displayed 
reduced tibial bone volume and area at all timepoints 
compared with the C group. The DPS group showed 
higher BVF, BSD, Tb. N, and BMD levels on days 3 and 
10 as well as greater tibial bone area on days 3, 10, and 
20 compared with the DP group. The number of TRAP-
positive osteoclasts in tibiae was higher in the DP group 
than in the C group and was lower in the DPS groups 
than in the DP group on day 3. These results suggest that 
systemic SIM treatment attenuated tibial bone loss and 
osteoclast formation under type 1 diabetic conditions at 
the early stage and the effect of SIM may weaken at later 
stage with severe bone loss.
Osteoblasts play an important role in bone forma-
tion through producing bone matrix proteins. In previ-
ous studies, SIM treatment improved bone formation 
by inhibiting osteoblast apoptosis through the trans-
forming growth factor (TGF)/SMAD family member 
3 signaling pathway as well as by stimulating osteoblast 
Fig. 2 The effects of SIM on serum lipid levels. The serum levels of a TG, b CHO, and c LDL of each group. Data are presented as the mean ± SE. 
*P < 0.05 compared with the C group. **P < 0.05. (C, n = 6; day 3: DP, n = 6 and DPS, n = 7; day 10: DP, n = 4 and DPS, n = 4; day 20: DP, n = 7 and DPS, 
n = 9)
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differentiation through induction of bone morphogenetic 
protein-2 expression [16]. Diabetes accelerates bone loss 
via suppression of bone formation. STZ-treated mice 
show decreased expression of osteoblast-specific genes 
(runt-related transcription factor 2, TGF-β) compared 
with non-diabetic mice [27]. Sclerostin is a WNT antago-
nist secreted by osteocytes that binds to LDL receptor-
related protein 5/6 and inhibits osteoblast differentiation 
[28]. STZ-treated mice showed increased sclerostin levels 
in serum and matrix embedded cells of the callus after 
femur fracture [29]. In the present study, the DP group 
also showed elevated proportions of sclerostin-positive 
osteocytes compared with the C group. Interestingly, the 
proportion of sclerostin-positive osteocytes in the DPS 
group was lower than the DP group, suggesting that SIM 
may improve bone formation in type 1 diabetes by inhib-
iting sclerostin expression in osteocytes.
Our previous work showed severe alveolar bone loss 
and inhibition of alveolar bone formation with elevated 
sclerostin expression on day 20 in rats with STZ-induced 
diabetes and periodontitis [23]. Therefore, to monitor the 
effect of systemic SIM treatment during the time of these 
changes, the timepoints selected for this study were days 
3, 10, and 20. However, we did not observe beneficial 
effects of SIM treatment on alveolar bone resorption and 
formation in type 1 diabetic rats with periodontitis. This 
suggests that systemic SIM administration during 20 days 
may not have beneficial effects on the severe alveo-
lar bone loss in type 1 diabetes with periodontitis. The 
effects of systemic SIM treatment have evaluated under 
various conditions. For example, systemic SIM treatment 
for 8  weeks reduced the number of osteoclasts in rats 
with LPS-induced periodontitis [5]. Further, systemic 
SIM treatment for 4 weeks decreased RANKL and colony 
stimulating factor 2 expressions in periodontal tissues of 
obese rats with LPS-induced periodontitis, suggesting an 
inhibitory effect of SIM on expression of osteoclastogen-
esis factors in rats with metabolic syndrome [14]. Finally, 
systemic SIM administration for 2  months prevented 
alveolar bone loss in ovariectomized rats with periodon-
titis [11]. The lack of response to systemic SIM treatment 
in terms of alveolar bone loss in type 1 diabetic rats with 
periodontitis in the present study may be due to differ-
ences in SIM administration time or the systemic disease 
model accompanied with periodontitis. To clarify the 
effect of SIM, it will be necessary to study prolonged sys-
temic SIM administration.
Fig. 3 The effects of SIM on alveolar bone loss and osteoid area. a ROI and representative images for the measurement of alveolar bone loss 
(H&E staining). The CEJ‑ABC distance in the distal area (upper panels, black arrow) and the alveolar bone area (pale blue color) in the ROI (black 
line) of the furcation (lower panels) were measured in each rat. b The measurement of the CEJ‑ABC distance in the distal area of each group. c 
Alveolar bone area as a percent of the ROI in the furcation of each group. d Osteoid area in the furcation of each group. Data are presented as the 
mean ± SE. Scale bar = 100 μm. *P < 0.05 compared with the C group. (C, n = 6; day 3: DP, n = 6 and DPS, n = 7; day 10: DP, n = 4 and DPS, n = 4; day 
20: DP, n = 7 and DPS, n = 9)
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Conclusions
In rats with type 1 diabetes and periodontitis, we did not 
observe significant prevention of periodontitis-induced 
alveolar bone loss during 20  days of systemic SIM 
administration. However, SIM attenuated tibial bone loss 
at early stage with weak bone loss, but not at late stage 
with sever bone loss. Moreover, SIM decreased the num-
ber of osteoclasts and proportion of sclerostin-positive 
Fig. 4 The effects of SIM on tibial bone loss. a Parameters of m‑CT analysis: BVF, BMD, BSD, and Tb. N in each group. (C, n = 5; day 3: DP, n = 5 and 
DPS, n = 5; day 10: DP, n = 4 and DPS, n = 4; day 20: DP, n = 5 and DPS, n = 6). b Trabecular bone area (pale blue color) in the ROI (black line) of tibiae 
(left panel, H&E staining, scale bar = 100 μm) and measurement of trabecular bone area in each group (right panel; C, n = 6; day 3: DP, n = 6 and 
DPS, n = 7; day 10: DP, n = 4 and DPS, n = 4; day 20: DP, n = 7 and DPS, n = 9). Data are presented as the mean ± SE. *P < 0.05 compared with the C 
group, **P < 0.05
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osteocytes in tibiae. Together, our results suggest that 
the effect of SIM on tibial bone loss may be related to the 
inhibition of osteoclast formation and sclerostin expres-
sion in type 1 diabetic rats with periodontitis. Our results 
provide useful information for establishing SIM as a ther-
apeutic strategy for systemic diseases with severe alveolar 
bone loss.
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